Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Martinez

Showing results (401-410 of 600) with videos related to

Pageof 60
Sort By:
Antiviral Therapy|February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week studyJosep M Llibre, Maria J Buzón, Marta Massanella, et al.
Plos Biology|December 29, 2012
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosidesNuria Izquierdo-Useros, Maier Lorizate, Maria C Puertas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2008
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infectionJudith Dalmau, Maria Carmen Puertas, Marta Azuara, et al.
Small (Weinheim an Der Bergstrasse, Germany)|March 19, 2020
Distortion-Free Sensing of Neural Activity Using Graphene TransistorsRamon Garcia-Cortadella, Eduard Masvidal-Codina, Jose M De la Cruz, et al.
Scientific Reports|October 4, 2017
HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trialRuth Blanco-Rojo, Pablo Perez-Martinez, Javier Lopez-Moreno, et al.
The Journal of Infectious Diseases|November 4, 2015
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral TherapySara Morón-López, Elisabet Gómez-Mora, Maria Salgado, et al.
Nature Medicine|March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsMaria J Buzón, Marta Massanella, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2018
Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected IndividualsSara Morón-López, Jordi Navarro, Montse Jimenez, et al.
Antiviral Therapy|January 18, 2005
Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch StudyEugenia Negredo, Roger Paredes, Joaquim Peraire, et al.
The Journal of Experimental Medicine|March 15, 2006
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virusRika Draenert, Todd M Allen, Yang Liu, et al.
Pageof 60

Showing results (401-410 of 600) with videos related to

Sort By:
Pageof 60
Antiviral Therapy|February 1, 2012
Treatment intensification with raltegravir in subjects with sustained HIV-1 viraemia suppression: a randomized 48-week studyJosep M Llibre, Maria J Buzón, Marta Massanella, et al.
Plos Biology|December 29, 2012
Siglec-1 is a novel dendritic cell receptor that mediates HIV-1 trans-infection through recognition of viral membrane gangliosidesNuria Izquierdo-Useros, Maier Lorizate, Maria C Puertas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 20, 2008
Contribution of immunological and virological factors to extremely severe primary HIV type 1 infectionJudith Dalmau, Maria Carmen Puertas, Marta Azuara, et al.
Small (Weinheim an Der Bergstrasse, Germany)|March 19, 2020
Distortion-Free Sensing of Neural Activity Using Graphene TransistorsRamon Garcia-Cortadella, Eduard Masvidal-Codina, Jose M De la Cruz, et al.
Scientific Reports|October 4, 2017
HDL cholesterol efflux normalised to apoA-I is associated with future development of type 2 diabetes: from the CORDIOPREV trialRuth Blanco-Rojo, Pablo Perez-Martinez, Javier Lopez-Moreno, et al.
The Journal of Infectious Diseases|November 4, 2015
Short-term Treatment With Interferon Alfa Diminishes Expression of HIV-1 and Reduces CD4+ T-Cell Activation in Patients Coinfected With HIV and Hepatitis C Virus and Receiving Antiretroviral TherapySara Morón-López, Elisabet Gómez-Mora, Maria Salgado, et al.
Nature Medicine|March 16, 2010
HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjectsMaria J Buzón, Marta Massanella, Josep M Llibre, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 28, 2018
Switching From a Protease Inhibitor-based Regimen to a Dolutegravir-based Regimen: A Randomized Clinical Trial to Determine the Effect on Peripheral Blood and Ileum Biopsies From Antiretroviral Therapy-suppressed Human Immunodeficiency Virus-infected IndividualsSara Morón-López, Jordi Navarro, Montse Jimenez, et al.
Antiviral Therapy|January 18, 2005
Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch StudyEugenia Negredo, Roger Paredes, Joaquim Peraire, et al.
The Journal of Experimental Medicine|March 15, 2006
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virusRika Draenert, Todd M Allen, Yang Liu, et al.
Pageof 60